Want to see HK:2235 full AI Analyst Report?
MicroTech Medical (Hangzhou) Co., Ltd. Class H (2235) Ratios
MicroTech Medical (Hangzhou) Co., Ltd. Class H Ratios
HK:2235's free cash flow for Q2 2026 was $7.94M. For the 2026 fiscal year, HK:2235's free cash flow was decreased by $-49.53M and operating cash flow was $57.47M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 6.39 | 11.41 | 21.67 | 26.61 | 27.12 |
| Quick Ratio | 6.11 | 11.11 | 21.22 | 25.79 | 26.71 |
| Cash Ratio | 5.32 | 10.17 | 20.19 | 25.02 | 26.12 |
| Solvency Ratio | 0.19 | -0.31 | -1.17 | -0.30 | -0.48 |
| Operating Cash Flow Ratio | 0.11 | -0.72 | -1.64 | -1.32 | -0.54 |
| Short-Term Operating Cash Flow Coverage | 0.35 | -29.88 | -34.63 | 0.00 | 0.00 |
| Net Current Asset Value | $ 1.52B | $ 1.73B | $ 1.93B | $ 2.09B | $ 2.15B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.15 | 1.09 | 1.05 | 1.04 | 1.04 |
| Debt Service Coverage Ratio | 0.34 | -25.75 | -38.95 | -749.63 | -2343.12 |
| Interest Coverage Ratio | 98.58 | -92.33 | -384.02 | -219.01 | -3539.18 |
| Debt to Market Cap | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.23 | 0.01 | 0.01 | 0.00 | 0.00 |
| Net Debt to EBITDA | -45.10 | 13.95 | 10.21 | 18.57 | 54.03 |
| Profitability Margins | |||||
| Gross Profit Margin | 54.09% | 52.91% | 49.62% | 45.90% | 46.82% |
| EBIT Margin | 2.70% | -38.12% | -78.64% | -69.34% | -31.79% |
| EBITDA Margin | 4.75% | -35.12% | -74.14% | -63.50% | -26.29% |
| Operating Profit Margin | 6.65% | -18.07% | -48.43% | -18.55% | -39.74% |
| Pretax Profit Margin | 6.11% | -18.27% | -50.27% | -20.19% | -31.80% |
| Net Profit Margin | 6.08% | -18.26% | -50.34% | -20.19% | -31.82% |
| Continuous Operations Profit Margin | 6.08% | -18.26% | -50.34% | -20.19% | -31.80% |
| Net Income Per EBT | 99.38% | 99.95% | 100.13% | 100.00% | 100.06% |
| EBT Per EBIT | 91.88% | 101.10% | 103.81% | 108.85% | 80.03% |
| Return on Assets (ROA) | 1.74% | -2.94% | -5.79% | -1.53% | -2.07% |
| Return on Equity (ROE) | 1.99% | -3.20% | -6.07% | -1.58% | -2.14% |
| Return on Capital Employed (ROCE) | 2.17% | -3.16% | -5.82% | -1.46% | -2.68% |
| Return on Invested Capital (ROIC) | 2.06% | -3.15% | -5.81% | -1.45% | -2.68% |
| Return on Tangible Assets | 1.76% | -2.98% | -5.88% | -1.54% | -2.08% |
| Earnings Yield | 1.40% | -2.62% | -5.36% | -0.96% | -0.62% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.41 | 2.91 | 3.38 | 3.51 | 5.45 |
| Payables Turnover | 3.49 | 2.17 | 3.90 | 4.11 | 5.70 |
| Inventory Turnover | 3.84 | 3.20 | 2.97 | 1.39 | 2.36 |
| Fixed Asset Turnover | 2.99 | 1.69 | 2.45 | 1.66 | 1.85 |
| Asset Turnover | 0.29 | 0.16 | 0.12 | 0.08 | 0.07 |
| Working Capital Turnover Ratio | 0.40 | 0.19 | 0.12 | 0.08 | 0.11 |
| Cash Conversion Cycle | 73.47 | 70.95 | 137.47 | 277.08 | 157.83 |
| Days of Sales Outstanding | 82.77 | 125.43 | 108.13 | 104.08 | 66.95 |
| Days of Inventory Outstanding | 95.17 | 113.94 | 122.85 | 261.78 | 154.87 |
| Days of Payables Outstanding | 104.46 | 168.41 | 93.51 | 88.77 | 63.98 |
| Operating Cycle | 177.94 | 239.36 | 230.98 | 365.86 | 221.82 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.08 | -0.29 | -0.36 | -0.25 | -0.12 |
| Free Cash Flow Per Share | -0.02 | -0.48 | -0.43 | -0.32 | -0.17 |
| Dividend Paid and CapEx Coverage Ratio | 0.84 | -1.44 | -5.33 | -3.62 | -2.36 |
| Capital Expenditure Coverage Ratio | 0.84 | -1.45 | -5.33 | -3.62 | -2.36 |
| Operating Cash Flow Coverage Ratio | 0.35 | -28.70 | -30.23 | -150.17 | -173.40 |
| Operating Cash Flow to Sales Ratio | 0.05 | -0.35 | -0.62 | -0.62 | -0.29 |
| Free Cash Flow Yield | -0.21% | -8.46% | -7.79% | -3.75% | -0.82% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 71.23 | -38.19 | -18.67 | -104.59 | -160.21 |
| Price-to-Sales (P/S) Ratio | 4.33 | 6.98 | 9.40 | 21.12 | 50.98 |
| Price-to-Book (P/B) Ratio | 1.42 | 1.22 | 1.13 | 1.66 | 3.44 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -468.34 | -11.82 | -12.84 | -26.67 | -122.65 |
| Price-to-Operating Cash Flow Ratio | 89.93 | -19.98 | -15.25 | -34.04 | -174.58 |
| Price-to-Earnings Growth (PEG) Ratio | -0.43 | 0.79 | -0.07 | 2.72 | 2.90 |
| Enterprise Value Multiple | 45.98 | -5.91 | -2.46 | -14.70 | -139.90 |
| Enterprise Value | 1.44B | 717.68M | 453.60M | 1.62B | 5.57B |
| EV to EBITDA | 45.98 | -5.91 | -2.46 | -14.70 | -139.90 |
| EV to Sales | 2.19 | 2.08 | 1.83 | 9.33 | 36.78 |
| EV to Free Cash Flow | -236.45 | -3.52 | -2.50 | -11.78 | -88.48 |
| EV to Operating Cash Flow | 45.40 | -5.95 | -2.96 | -15.04 | -125.94 |
| Tangible Book Value Per Share | 4.97 | 4.62 | 4.76 | 5.17 | 5.98 |
| Shareholders’ Equity Per Share | 5.02 | 4.69 | 4.84 | 5.20 | 6.02 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.01 | -0.00 | -0.00 | -0.00 | -0.00 |
| Revenue Per Share | 1.65 | 0.82 | 0.58 | 0.41 | 0.41 |
| Net Income Per Share | 0.10 | -0.15 | -0.29 | -0.08 | -0.13 |
| Tax Burden | 0.99 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 2.27 | 0.48 | 0.64 | 0.29 | 1.00 |
| Research & Development to Revenue | 0.12 | 0.22 | 0.28 | 0.18 | 0.10 |
| SG&A to Revenue | 0.26 | 0.44 | 0.06 | 0.24 | 0.28 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.08 |
| Income Quality | 0.81 | 1.91 | 1.22 | 3.07 | 0.92 |
Currency in CNY